Elamipretide — Mitochondria-Targeting Peptide
A tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it stabilises cardiolipin — a phospholipid critical for the electron transport chain and ATP synthesis. SS-31 is arguably the most mechanistically precise mitochondrial peptide in the research space, with Phase 2 human trial data across heart failure, kidney disease, and aging. Plasma levels of its endogenous targets decline significantly with age, making it one of the most compelling compounds in the longevity peptide arsenal.
01 — Research Summary
SS-31 has an impressive research portfolio spanning from foundational cardiolipin biochemistry through Phase 2 clinical trials in heart failure and renal disease — giving it one of the strongest human evidence bases of any emerging longevity peptide.
Significant improvement in cardiac function and exercise capacity. A Phase 2 randomised controlled trial in heart failure with preserved ejection fraction (HFpEF) showed SS-31 intravenous infusion significantly improved six-minute walk distance and quality of life measures — the primary endpoints — in a condition with very limited therapeutic options.
Improved mitochondrial function in older adults. A human study in older adults showed SS-31 treatment improved mitochondrial energetics in skeletal muscle — measured by 31P-MRS — alongside improved walking speed and muscle strength. One of the clearest demonstrations of mitochondrial function restoration in humans.
Reduced contrast-induced kidney injury. Phase 2 data showed SS-31 reduced acute kidney injury following cardiac surgery in high-risk patients, demonstrating its cytoprotective mechanism in a clinical setting with measurable hard endpoints.
Extended healthy lifespan in multiple animal models. Animal studies across multiple species showed SS-31 extended both median and maximum lifespan while preserving physical function, cognitive performance, and metabolic health — providing the longevity rationale for its growing use in anti-aging protocols.
02 — Mechanism of Action
SS-31's mechanism is unusually specific — it targets a single phospholipid (cardiolipin) in a specific subcellular location (the inner mitochondrial membrane). This precision explains both its efficacy and its clean safety profile.
SS-31's alternating aromatic and basic amino acid structure gives it a high affinity for the inner mitochondrial membrane. It concentrates approximately 1,000-fold in mitochondria relative to cytoplasm — a targeting efficiency that makes it among the most mitochondria-selective compounds known.
Inside the inner membrane, SS-31 binds cardiolipin — a unique phospholipid found almost exclusively in the inner mitochondrial membrane. Cardiolipin is essential for the structural organisation of the electron transport chain complexes, and its oxidation and loss is a central feature of mitochondrial aging.
By stabilising cardiolipin, SS-31 restores the structural integrity of electron transport chain supercomplexes (particularly Complex I and Complex III), improving electron transfer efficiency and reducing electron leak — the primary source of mitochondrial reactive oxygen species.
With the electron transport chain functioning more efficiently, reactive oxygen species production drops and ATP synthesis increases simultaneously. This dual benefit — less oxidative damage plus more cellular energy — explains SS-31's broad protective effects across multiple organ systems.
SS-31 also appears to support mitochondrial quality control mechanisms, including mitophagy — the selective removal of damaged mitochondria. This housekeeping function prevents accumulation of dysfunctional mitochondria that would otherwise amplify ROS production.
SS-31 and MOTS-c are both mitochondrial peptides but work through completely different mechanisms. SS-31 protects mitochondrial membrane structure and restores electron transport chain function — it's essentially a repair compound. MOTS-c acts as a metabolic signal that activates AMPK and drives metabolic adaptation — it's more of an activator. They are highly complementary and frequently stacked in longevity protocols targeting comprehensive mitochondrial optimisation.
03 — Dosing Protocols
SS-31 dosing in community protocols is adapted from Phase 2 trial protocols. The subcutaneous route is standard for community use; IV administration used in clinical trials.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Standard community protocol | 2–5 mg | Daily subcutaneous | 4–8 weeks | Most common community dose adapted from preclinical and Phase 2 data. |
| Conservative start | 1–2 mg | Daily | 2 weeks then reassess | Lower starting dose to assess tolerance. Minimal side effects expected. |
| Longevity cycling protocol | 2–5 mg | 5 days on / 2 off | Indefinite cycles | Cycling protocol used in longevity stacks. Rest days to maintain sensitivity. |
| Clinical (IV) | 0.05–0.25 mg/kg | Single infusion | Clinical setting only | Phase 2 trial doses administered intravenously under medical supervision. |
SS-31 has an excellent safety profile in both preclinical and Phase 2 human trial data. Injection site reactions are the primary reported side effect. The compound is expensive relative to most research peptides. Monitor for injection site reactions and rotate sites. Not FDA-approved for any indication.
04 — Community Experiences
SS-31 has a smaller but highly informed community — primarily serious longevity researchers and biohackers who have moved beyond mainstream peptides into frontier compounds. Discussions on r/longevity and r/Peptides are notable for their sophistication, frequently referencing the Phase 2 trial data and the cardiolipin mechanism. The mitochondrial stack combining SS-31, MOTS-c, and NAD+ is one of the most discussed advanced longevity protocols.
These are user-reported experiences from public forums. Not endorsed by Whats That Peptide and should not be interpreted as clinical evidence. Individual results vary. Always consult a healthcare professional.
"The cardiolipin mechanism is genuinely elegant. You're not just stimulating a pathway — you're restoring the structural integrity that makes the entire electron transport chain work properly. The Phase 2 heart failure data is real clinical validation..."
"Running all three for 6 months. SS-31 for membrane protection, MOTS-c for AMPK activation, NAD+ for the sirtuin pathway. Energy levels meaningfully better. Cognitive clarity improved. Sleep quality up. The combination feels like more than the sum of parts..."
"It's expensive. The synthesis is complex and quality varies. If you're going to run SS-31, COA verification is non-negotiable. The compounds are inert-looking — you genuinely cannot tell quality from appearance. Triple-tested suppliers only..."
"The 31P-MRS data from the human aging study is the kind of objective evidence that makes me take a compound seriously. They didn't just measure subjective outcomes — they measured actual mitochondrial energetics in muscle tissue. The improvement was significant..."